New Cytotoxic Drugs in Treatment of Breast Cancer

References

• Henderson I C, Canellos G P. Cancer of the breast. The past decade. New Engl J Med 1980; 302: 78–90
   PubMed Web of Science ®Google Scholar
• Henderson I C. New agents and new medical treatments for advanced breast cancer. Semin Oncol 1987; 14: 34–64
   PubMed Web of Science ®Google Scholar
• Carlsson R W, Billingham M E, Kohler M, Johnson F D, Doroshaw J H, Tarti F M. Esorubicin in refractory metastatic carcinoma of the breast: a Northern California Oncology Group Study. Cancer Treat Rep 1987; 71: 427–8
   Google Scholar
• van Oosterom A T, Mouridsen H T, Wilders J, et al. Carminomycin versus doxorubicin in advanced breast cancer, a randomized phase II study of the EORTC Breast Cancer Cooperative Group. Eur J Cancer Clin Oncol 1986; 22: 601–5
   Google Scholar
• Cowan J D, Osborne C K, Neidhart J A, von Hoff D D, Coustanzi J J, Vaughn C B. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer. (A South West Oncology Group Study.). Invest New Drugs 1985; 3: 149–52
   PubMed Web of Science ®Google Scholar
• Rozencweig M, Huinink W TB, Cavalli F, et al. Randomized phase II trial of carminomycin versus 4-epidoxorubicin in advanced breast cancer. J Clin Oncol 1984; 2: 275–81
   Google Scholar
• Martoni A, Pacciarini M A, Panutti F. Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer. Eur J Cancer Clin Oncol 1985; 21: 803–6
   PubMedGoogle Scholar
• Lionetto R, Pronzato P, Conte P F, Sertoli M R, Amoroso D, Rosso R. Idarubicin in advanced breast cancer: A phase II study. Cancer Treat Rep 1986; 70: 1439–40
   PubMedGoogle Scholar
• Kolaric K, Meehl Z, Potrebica V, Sopkova B. Phase I study of oral 4-demethoxydaunorubicin in previously treated (exept anthracyclines) metastastic breast cancer patients. Oncology 1987; 44: 82–6
   PubMed Web of Science ®Google Scholar
• Casper E S, Raymond V, Hakes T B, Currie V E, Kaufman R J. Phase II evaluation of orally administered idarubicin in patients with advanced breast cancer. Cancer Treat Rep 1987; 71: 1289–93
   PubMedGoogle Scholar
• Bastholt L, Dalmark M, Jakobsen A, Gadeberg C C, Sandberg E, Mouridsen H T. Oral idarubicin in the treatment of advanced breast cancer. Acta Oncol 1989; 28: 893–7
   PubMed Web of Science ®Google Scholar
• Smith D B, Howell A. A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer. Eur J Cancer Clin Oncol 1987; 23: 391–4
   PubMedGoogle Scholar
• Lopez M, DiLauro L, Papaldo P, Lazarro B, Ganzina F, DiPetro N. Phase II trial with oral idarubicin in advanced breast cancer. Invest New Drugs 1986; 4: 39–42
   PubMed Web of Science ®Google Scholar
• Bastholt L, Dalmark M. Phase II study of idarubicin given orally in the treatment of anthracycline-naïve advanced breast cancer patients. Cancer Treat Rep 1987; 71: 451–4
   PubMedGoogle Scholar
• Jain K K, Casper E S, Geller N L, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985; 3: 818–26
   PubMed Web of Science ®Google Scholar
• Brambilla C, Rossi A, Bonfante V, et al. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 1986; 70: 261–6
   PubMedGoogle Scholar
• van Oosterom A T, Andersson M, Wildiers J, et al. Adriamycin (A) versus 4-epi-adriamycin (E). Report of a secondline randomized phase III study in advanced breast cancer (Trial 10811). (Abstract 1.6) Proc. IV EORTC Breast Cancer Working Conference, London, 1987
   Google Scholar
• Italian Multicentre Breast Study with Epirubicin. Phase III randomized study of fluorouracil, epirubicin and cyclophosphamide v fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer: An Italian Multicenter Trial. J Clin Oncol 1988; 6: 976–82
   PubMedGoogle Scholar
• French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 1988; 6: 679–99
   PubMed Web of Science ®Google Scholar
• Khater R, Namer Herym M. F. Weekly low-dose adriamycin in poor prognosis patients with advanced breast cancer. (Abstract 156) 12th Annual Meeting ESMO, Nice, 1986
   Google Scholar
• Sigurdsson H, Johansson-Terje I, Aspegren K, et al. Weeklydose doxorubicin (WDA) in advanced breast cancer. Radiother Oncol 1986; 7: 133–9
   PubMedGoogle Scholar
• Gundersen S, Kvinnsland S, Klepp S, Kvaløy S, Lund E, Høst H. Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. J Cancer Clin Oncol 1986; 22: 1431–4
   PubMedGoogle Scholar
• Elomaa I, Blomqvist C, Rissanen P. Weekly low-dose doxorubicin as second line therapy in advanced breast cancer. Acta Oncol 1988; 27: 799–801
   PubMed Web of Science ®Google Scholar
• Berette G, Locatelli C, Tabiadon D, Labianca R, Fraschini P, Luporini G. Epirubicin treatment of advanced breast carcinoma with the weekly low-dose regimen. Oncology 1987; 44: 6–12
   Google Scholar
• Jones W G. Effective palliation of advanced breast cancer with weekly low-dose epirubicin. Eur J Cancer Clin Oncol 1989; 25: 357–60
   PubMedGoogle Scholar
• Mouridsen H T, Arlin Z A. The role of mitoxantrone in malignant diseases. PharmaLibri, Chicago, Tokyo, Sidney 1987
   Google Scholar
• Henderson I C. Mitoxantrone for advanced breast cancer. Comparisons with other standard agents. he role of mitoxantrone in malignant diseases, H T Mouridsen, Z A Arlin. PharmaLibri, Chicago, Tokyo, Zurich 1977; 49–66
   Google Scholar
• Neidhart J A, Gochnour D, Roach R, et al. A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 1986; 4: 672–7
   PubMed Web of Science ®Google Scholar
• Cowan J D, Osborne C K, Costanzi J J, et al. Randomized trial of novantrone (N) bisantrene (B) and adriamycin (A) in advanced breast cancer. Proc. ASCO 1986; 5: 59
   Google Scholar
• Bennett J M, Muus H B, Doroshow J H, et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide and fluorouracil with doxorubicin cyclophosphamide and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 1988; 6: 1611–20
   PubMed Web of Science ®Google Scholar
• Grøhn P. A comparative randomised study of mitoxantrone and doxorubicin combination therapy in advanced breast cancer. (Abstract) Second Nordic Novantrone Symposium. Oslo 1988
   Google Scholar
• Loprinzi C L, Carbone P P. Breast cancer. Cancer chemotherapy annual. 6, H M Pinedo, B A Chabner. Elsevier Sci Publ BV. 1984; 398–426
   Google Scholar
• Loprinzi C L, Carbone P P. Breast cancer. Cancer chemotherapy 7, H M Pinedo, B A Chabner. Elsevier Sci Publ BV. 1985; 396–416
   Google Scholar
• Loprinzi C L, Carbone P P. Breast cancer. Cancer chemotherapy 8, H M Pinedo, B A Chabner. Elsevier Sci Publ BV. 1986; 460–83
   Google Scholar
• Loprinzi C L, Carbone P P. Breast cancer. Cancer chemotherapy and biological response modifiers annual 9, H M Pinedo, D L Longo, B A Chabner. Elsevier Sci Publ BV. 1987; 338–57
   Google Scholar
• Hartman L C, Loprinzi C L. Breast cancer. Cancer chemotherapy and biological response modifiers annual 10, H M Pinedo, D L Longo, B A Chabner. Elsevier Sci Publ BV. 1988; 313–32
   Google Scholar
• Yap H Y, Salem P, Hortobagyi G N, et al. Phase II study of cis-dichlorodiammineplatinum (II) in advanced breast cancer. Cancer Treat Rep 1978; 62: 405–8
   PubMedGoogle Scholar
• Forastiere A A, Hakes T B, Wittes J T, et al. Cisplatin in the treatment of metastatic breast cancer. Am J Clin Oncol 1982; 5: 243–7
   PubMed Web of Science ®Google Scholar
• Martino S, Samal B A, Singhakowinta A, et al. A phase II study of cis-diamminedichloroplatinum (II) for advanced breast cancer. Two-dose schedules. J Cancer Res Clin Oncol 1984; 108: 354–6
   PubMed Web of Science ®Google Scholar
• Kolaric K, Roth A. Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 1983; 11: 108–12
   PubMed Web of Science ®Google Scholar
• Sledge G W, Loehrer P J, Roth B J, Einhorn L H. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 1988; 6: 1811–4
   PubMed Web of Science ®Google Scholar
• Creagan E T, Green S J, Ahmann D L, Ingle J N, Edmonson J, Marschke H. RF. A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer. J Clin Oncol 1984; 2: 1260–5
   Google Scholar
• Kolaric K, Roth A, Vukas D, Cervek J. CAP (cyclophosphamide, adriamycin, platinum) vs. CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study. Cancer Chemother Pharmacol 1984; 13: 142–4
   Google Scholar
• Løber J, Mouridsen H T, Christiansen I E, Dombernowsky P, Mattson W, Rørth M. A phase II trial comparing prednimustine (Leo 1031) to chlorambucil plus prednisolone in advanced breast cancer. Cancer 1983; 52: 1570–6
   Google Scholar
• Yosef H, Slater A, Bunting I S, (1987) SMF versus CMF in treatment of advanced breast cancer. Sterecyt. Proceedings of a satellite symposium Hamburg. 1987, S Seeber, M Kaufmann, et al. AB Leo, Helsingborg, 29–39
   Google Scholar
• Bodenstein H, Preiss J, Hilfrich J, (1987) Treatment of metastatic breast cancer with novantrone and sterecyt—an efficient therapy and low subjective toxicity. Sterecyt. Proceedings of a satellite symposium, Hamburg. 1987, S Seeber, M Kaufmann, et al. AB Leo, Helsingborg, 53–9
   Google Scholar
• Schmid H, Raeth U, Manegold C, Kaufmann M. (1987) Prednimustine and mitoxantrone (NOSTE) in the treatment of advanced breast cancer. Sterecyt. Proceedings of a satellite symposium, Hamburg. 1987, S Seeber, M Kaufmann. AB Leo, Helsingborg, 43–53
   Google Scholar
• Andersson M, Mouridsen H T. Prednimustine, methotrexate, 5-fluorouracil, mitoxantrone and tamoxifen for advanced breast cancer in postmenopausal women. A phase II trial. Acta Oncol 1988; 27: 235–9
   Web of Science ®Google Scholar
• Yap H Y, Blumenschein G R, Hortobagyi G N, et al. A randomized comparative study of vinblastine (vlb) vindesine (vds) and vincristine (vcr) in patients (pts) with refractory metastatic breast cancer. (Abstract) Proc ASCO 1981; 22: 441
   Google Scholar
• Fleishman G B, Yap H Y, Bodey G P, et al. Comparability in therapeutic index with continous 5-day infusion and 5-day bolus vindesine in the treatment of refractory breast cancer. (Abstract) Proc. ASCO 1982; 1: 82
   Google Scholar
• Rasmussen D, Jensen J, Skovsgaard T, Andersen E, Hansen M, Dombernowsky P. Epirubicin (E) versus epirubicin and vindesine (V) in advanced breast cancer. (Abstract 234) 12 Annual Meeting ESMO, Nice, 1986
   Google Scholar